stockrowVericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
Follow VCEL
Alert me
Vericel Corporation (VCEL) Current ratio
Vericel Corporation's current ratio at the end of the quarter to 30 September 2026 was 5.1×, up 0.1× from fiscal 2025 (5.0×). Over the past ten years it has ranged from 2.3× (fiscal 2015) to 7.6× (fiscal 2018); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 5.0× | 18.98% |
| FY2024 | 4.2× | (5.86%) |
| FY2023 | 4.5× | (9.89%) |
| FY2022 | 5.0× | (17.99%) |
| FY2021 | 6.1× | 10.68% |
| FY2020 | 5.5× | (2.57%) |
| FY2019 | 5.6× | (26.02%) |
| FY2018 | 7.6× | 97.61% |
| FY2017 | 3.9× | 10.89% |
| FY2016 | 3.5× | 54.08% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 5.1× | 1.82% |
| Jun 2026 | 5.0× | (2.64%) |
| Mar 2026 | 5.2× | 2.81% |
| Dec 2025 | 5.0× | 3.38% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | 21.2× |
| IMNM Immunome, Inc. compare | 15.1× |
| PHVS Pharvaris N.V. compare | 11.9× |
| CLDX Celldex Therapeutics, Inc. compare | 11.8× |
| VERA Vera Therapeutics, Inc. compare | 10.9× |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.1× |
| ADMA ADMA Biologics Inc compare | 6.0× |
| VCEL Vericel Corporation | 5.1× |
| BHVN Biohaven Ltd. compare | 3.1× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on VCEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement